CN110248649A - (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 - Google Patents
(+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 Download PDFInfo
- Publication number
- CN110248649A CN110248649A CN201780085223.4A CN201780085223A CN110248649A CN 110248649 A CN110248649 A CN 110248649A CN 201780085223 A CN201780085223 A CN 201780085223A CN 110248649 A CN110248649 A CN 110248649A
- Authority
- CN
- China
- Prior art keywords
- drug
- expression
- sphingosine kinase
- regulation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title claims abstract description 37
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims abstract description 35
- 108010035597 sphingosine kinase Proteins 0.000 title claims abstract description 32
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 title claims abstract description 26
- 241000723346 Cinnamomum camphora Species 0.000 title claims abstract description 26
- 229960000846 camphor Drugs 0.000 title claims abstract description 26
- 229930008380 camphor Natural products 0.000 title claims abstract description 26
- 102100039024 Sphingosine kinase 1 Human genes 0.000 title claims abstract description 25
- 230000003827 upregulation Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims abstract description 31
- 206010008118 cerebral infarction Diseases 0.000 claims description 10
- 201000006474 Brain Ischemia Diseases 0.000 claims description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 206010004954 Birth trauma Diseases 0.000 claims description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 208000019743 Cranial nerve injury Diseases 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims 3
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 15
- 210000002569 neuron Anatomy 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 210000005036 nerve Anatomy 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 7
- 206010061216 Infarction Diseases 0.000 abstract description 6
- 230000007574 infarction Effects 0.000 abstract description 6
- 230000004083 survival effect Effects 0.000 abstract description 6
- 210000001130 astrocyte Anatomy 0.000 abstract description 5
- 230000005012 migration Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 230000014511 neuron projection development Effects 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 4
- 238000009792 diffusion process Methods 0.000 abstract description 4
- 238000012153 long-term therapy Methods 0.000 abstract description 4
- 210000004248 oligodendroglia Anatomy 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 208000022306 Cerebral injury Diseases 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 21
- 108010025020 Nerve Growth Factor Proteins 0.000 description 12
- 102000015336 Nerve Growth Factor Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 101150080374 Sphk1 gene Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 7
- 108091008611 Protein Kinase B Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004112 neuroprotection Effects 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003520 dendritic spine Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- -1 sphingol Chemical compound 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Camphene hydrate Chemical group C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 102100027662 Sphingosine kinase 2 Human genes 0.000 description 1
- 101710156532 Sphingosine kinase 2 Proteins 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
本文公布了(+)‑2‑莰醇在制备促进鞘氨醇激酶‑1和/或BDNF(脑源性神经营养因子)表达上调的药物中的应用，在本文中，(+)‑2‑莰醇可以用于制备促进鞘氨醇激酶‑1和/或脑源性神经营养因子表达上调的药物，该药物可以诱发星形胶质细胞扩散和迁移、少突细胞分化和生存、神经突生长和神经再生，并且可以促进脑源性神经营养因子的表达上调，促进神经元的存活和轴突的生长，抑制梗死体积扩大，实现在防止梗塞面积的进一步扩大同时对直接损伤部位达到修复损伤的功效，以彻底解决脑损伤，使得其远期治疗效果显著提升。
Description
PCT国内申请，说明书已公开。
Claims (12)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/092148 WO2019006734A1 (zh) | 2017-07-07 | 2017-07-07 | (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110248649A true CN110248649A (zh) | 2019-09-17 |
Family
ID=64950502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780085223.4A Pending CN110248649A (zh) | 2017-07-07 | 2017-07-07 | (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200261375A1 (zh) |
| EP (1) | EP3578174A4 (zh) |
| JP (1) | JP6951449B2 (zh) |
| CN (1) | CN110248649A (zh) |
| WO (1) | WO2019006734A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518057A (zh) * | 2021-10-18 | 2022-12-27 | 苏州沪云新药研发股份有限公司 | 莰醇在制备治疗缺血性脑卒中的药物中的用途 |
| WO2023065071A1 (zh) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | 莰醇在制备治疗缺血性脑卒中的药物中的用途 |
| CN116919930A (zh) * | 2022-04-06 | 2023-10-24 | 沈阳药科大学 | 萜类化合物在调节脑膜淋巴循环促进脑内异常蛋白通过淋巴途径清除中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102180832A (zh) * | 2011-03-18 | 2011-09-14 | 苏州沪云肿瘤研究中心有限公司 | 脑缺血保护用化合物及制备方法 |
| CN105879036A (zh) * | 2016-04-14 | 2016-08-24 | 成都大学 | 一种冰片和载药纳米粒的组合物在治疗脑部疾病中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012292A (zh) * | 2014-04-17 | 2015-11-04 | 米文君 | 一种药物组合物及其用途 |
| CN105232528A (zh) * | 2014-07-10 | 2016-01-13 | 米文君 | 一种药物组合物及其用途 |
-
2017
- 2017-06-07 US US16/488,062 patent/US20200261375A1/en not_active Abandoned
- 2017-07-07 JP JP2019537248A patent/JP6951449B2/ja active Active
- 2017-07-07 CN CN201780085223.4A patent/CN110248649A/zh active Pending
- 2017-07-07 WO PCT/CN2017/092148 patent/WO2019006734A1/zh unknown
- 2017-07-07 EP EP17916830.7A patent/EP3578174A4/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102180832A (zh) * | 2011-03-18 | 2011-09-14 | 苏州沪云肿瘤研究中心有限公司 | 脑缺血保护用化合物及制备方法 |
| CN105879036A (zh) * | 2016-04-14 | 2016-08-24 | 成都大学 | 一种冰片和载药纳米粒的组合物在治疗脑部疾病中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020504152A (ja) | 2020-02-06 |
| EP3578174A1 (en) | 2019-12-11 |
| WO2019006734A1 (zh) | 2019-01-10 |
| US20200261375A1 (en) | 2020-08-20 |
| JP6951449B2 (ja) | 2021-10-20 |
| EP3578174A4 (en) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chmielarz et al. | Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies | |
| Chou et al. | CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model | |
| Kayaba et al. | Attenuated defense response and low basal blood pressure in orexin knockout mice | |
| Grasso | Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage | |
| US20200163961A1 (en) | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | |
| Mahadik et al. | Gangliosides in treatment of neural injury and disease | |
| US8313744B2 (en) | Composition for the prevention and treatment of absence seizures comprising PKC agonist as an effective ingredient | |
| CN110248649A (zh) | (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 | |
| Carrive | Orexin, stress and central cardiovascular control. A link with hypertension? | |
| CN108025005A (zh) | 神经退行性疾病的治疗 | |
| US20200384001A1 (en) | Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase | |
| JP6903577B2 (ja) | 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 | |
| Paulzen et al. | Effects of psychotropic drugs on brain plasticity in humans | |
| KR101478304B1 (ko) | 신경염증 질환의 예방 또는 치료용 약학 조성물 | |
| AU2011285703B2 (en) | Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury | |
| Holden et al. | An NK1 receptor antagonist microinjected into the periaqueductal gray blocks lateral hypothalamic-induced antinociception in rats | |
| Kim et al. | Downregulation of neurotrophic factors in the brain of a mouse model of Gaucher disease: Implications for neuronal loss in Gaucher disease | |
| Arushanyan et al. | The hippocampus and cognitive impairments | |
| Panjala et al. | Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of dopamine beta hydroxylase (Dbh−/−) knockout mice | |
| Li et al. | P2Y6 Receptor Activation Aggravates NLRP3-dependent Microglial Pyroptosis via Downregulation of the PI3K/AKT Pathway in a Mouse Model of Intracerebral Hemorrhage | |
| Li et al. | P2RY6 activation aggravates NLRP3-dependent microglial pyroptosis via down-regulation of the PI3K/AKT pathway in a mouse model of intracerebral hemorrhage | |
| Wang et al. | Xylazole inhibits NO-cGMP pathway in fetal rat nerve cells | |
| CN110652506A (zh) | 三醋酸甘油酯在制备预防和治疗抑郁症药物中的用途 | |
| Mercado-Idziak | Toward Precision Medicine: Effects of the Common VAL66met BDNF Variant in the Aging Brain and Implications for the Future of Parkinson’S Disease Therapeutics | |
| Poniatowski et al. | Dose-Ranging Effects of the Intracerebral Administration of Atsttrin in Experimental Model of Parkinson’s Disease Induced by 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |